Interrupted time series analysis for impacts of the inclusion of group A and C meningococcal polysaccharide vaccine in the Expanded Program on Immunization on the incidence of meningococcal meningitis / 公共卫生与预防医学

Objective To evaluate the impact of the inclusion of (MPSV-AC) vaccine in the Expanded Program on Immunization (EPI) on the incidence of meningococcal meningitis. Methods Data on the incidence of meningococcal meningitis in Liaoning from 1995 to 2019 were collected, Interrupted time series (ITS) analysis was used to assess the level and slope change of the incidence of meningococcal meningitis before and after the inclusion of MPSV-AC vaccine in the EPI. Results Before the MPSV-AC vaccine was included in the EPI, the average annual incidence rate of meningococcal meningitis was 0.3442/100 000, the incidence rate showed a descending trend with an annual decrement of 0.0319/100 000. After the MPSV-AC vaccine was included in the EPI, the average annual incidence rate of meningococcal meningitis was 0.0151/100 000 and he incidence of meningococcal meningitis showed a descending trend with an annual decrement of 0.0042/100 000. Conclusion The incidence of meningococcal meningitis reduced after the inclusion of MPSV-AC vaccine in EPI，and the EPI strategy had a continuous effect on the decreasing trend of meningococcal meningitis incidence.

Seasonal Meningococcal Meningitis Outbreaks in Nigeria: A Need for an Accelerated Introduction of a Conjugated Meningococcal Vaccine into the National Routine Immunization Schedule

Epidemic meningococcal meningitis affects huge populations annually in sub-Saharan Africa with differentially higher death rates among children. Nigeria is one of the twenty-six countries that lie in ‘African meningitis belt’. This paper briefly describes the epidemiology of seasonal recurrent meningococcal meningitis, current efforts to address the epidemics, and then argues for an accelerated introduction of conjugated meningococcal vaccine into routine immunization in Nigeria. This paper also highlights the nature of the epidemics with its attendant impacts on the population; the weaknesses of the current strategies; the emergence of mixed pathogens; the challenges and potential opportunities associated with an introduction of routine vaccination against meningococcal meningitis. The quick introduction of the conjugated meningococcal vaccine into expanded program on immunization (EPI) schedule will mitigate the risk of future massive outbreaks and its attendant morbidity, mortality and larger societal cost. Furthermore, authors suggest the introduction of polyvalent conjugated meningococcal vaccine rather than monovalent (targeting only serotype A), as this will potentially prevent emerging outbreaks of other serotypes such as NmC and W135.

Vacuna cubana antimeningocócica VA-MENGOC-BC®: Treinta años de uso y potencialidades vigentes / Cuban Meningococcal Vaccine VA-MENGOC-BC®: 30 Years of Use and Future Potential

La enfermedad meningocócica provoca cada año más de 500.000 casos y 85.000 muertes en el mundo y un 20 por ciento de los sobrevivientes sufre secuelas. En Cuba, en 1980, la incidencia llegó a 14,4 por 100.000 habitantes para todas las edades y fue declarada como el principal problema de salud del país. En niños menores de 1 año se reportaron más de 120 casos por 100.000 habitantes en algunas provincias. En 1989, investigadores en La Habana, Cuba desarrollaron una vacuna contra meningococo B y C; VA-MENGOC-BC®, la primera en el mundo eficaz contra el meningococo del serogrupo B. Su eficacia de 83 por ciento se demostró en un estudio de campo prospectivo a doble ciegas, aleatorizado, contra placebo. En su producción se empleó por primera vez la tecnología vesicular o proteoliposómica. Esta vacuna se usó en una campaña de vacunación masiva y posteriormente fue incluida en el Programa Ampliado de Inmunización en Cuba y tuvo un impacto acumulado sobre la incidencia de la enfermedad meningocócica del serogrupo B superior a 95 por ciento (93 por ciento-98 por ciento). La vacunación masiva y sistemática cambió el espectro de cepas del meningococo en los portadores asintomáticos sanos y la circulación de cepas en las poblaciones hacia fenotipos no virulentos. La enfermedad dejó de ser un problema de salud en el país. VA-MENGOC-BC® es la vacuna contra la enfermedad meningocócica del serogrupo B que se aplicó en el mayor número de susceptibles en el mundo. En América Latina se administraron más de 60 millones de dosis. En varios países donde se ha usado VA-MENGOC-BC®, circulan cepas diferentes a la vacunal y contra todas ellas se demostró un elevado porcentaje de efectividad (55%-98 por ciento en menores de 4 años y 73 por ciento-100 por ciento en mayores de 4 años). VA-MENGOC-BC® y su tecnología proteoliposómica han tenido impacto y mantienen su potencialidad, no solo en la enfermedad meningocócica, sino en el desarrollo de otras vacunas y adyuvantes(AU)

Every year, meningococcal infection by Neisseria meningitidis causes over 500,000 cases and 85,000 deaths in the world, with 20 percent of survivors suffering sequelae. In Cuba its incidence in 1980 reached 5.9 cases per 100,000 population; about 80 percent of cases were serogroup B, prompting health authorities to declare meningococcal disease the country's main public health problem. Several provinces reported over 120 cases per 100,000 children aged <1 year, overwhelmingly serogroup B. At that time, no vaccines existed with proven efficacy against N. meningitidis serogroup B, nor was there a vaccine candidate that could be successful in the short term. By 1989, researchers in Havana had developed a Cuban meningococcal B and C vaccine, VA-MENGOC-BC®, the world's first against serogroup B meningococcal disease. Its efficacy of 83 percent was demonstrated in a prospective, randomized, double-blind, placebo-controlled field study. Vaccine production used vesicle or proteoliposome technology for the first time. The same year, the World Intellectual Property Organization awarded its gold medal to the main authors of the VA-MENGOC-BC® patent. The vaccine was used in a mass vaccination campaign and later included in Cuba's National Immunization Program, with a cumulative impact on incidence of serogroup B meningococcal disease greater than 95 percent (93 percent-98 percent). Mass, systematic vaccination shifted the spectrum of meningococcal strains in healthy asymptomatic carriers and strains circulating among population groups toward nonvirulent phenotypes. The disease ceased to be a public health problem in the country. VA-MENGOC-BC® is the most widely applied vaccine against serogroup B meningococcal disease in the world. Over 60 million doses have been administered in Latin America. In several countries where it has been applied, in which strains other than the vaccine-targeted strains circulate, VA-MENGOC-BC® has demonstrated effectiveness against all (55 percent-98 percent in children aged ≥4 years and 73 percent-100 percent in children aged >4 years). The vaccine and its proteoliposome technology have had an impact and continue to have potential, not only for meningococcal disease, but also for development of other vaccines and adjuvants(AU)

Experts' consensus on immunization with meningococcal vaccines in China / 中华流行病学杂志

Meningococcal vaccines in the Chinese market include meningococcal polysaccharide vaccine,meningococcal polysaccharide conjugate vaccine,and a combined vaccine.Meningococcal conjugate vaccines immunization schedules vary by vaccine manufacturer,and often cause confusion in immunization practices.Based on the epidemiological characteristics of meningococcal disease,serogroup distribution of Neisseria meningitidis,and research progress on the immunogenicity and safety of meningococcal vaccines,we developed an experts' consensus on immunization with meningococcal vaccines to provide guidance for immunization providers and for centers for disease control and prevention staff.

Experts' consensus on immunization with meningococcal vaccines in China / 中华流行病学杂志

Meningococcal vaccines in the Chinese market include meningococcal polysaccharide vaccine,meningococcal polysaccharide conjugate vaccine,and a combined vaccine.Meningococcal conjugate vaccines immunization schedules vary by vaccine manufacturer,and often cause confusion in immunization practices.Based on the epidemiological characteristics of meningococcal disease,serogroup distribution of Neisseria meningitidis,and research progress on the immunogenicity and safety of meningococcal vaccines,we developed an experts' consensus on immunization with meningococcal vaccines to provide guidance for immunization providers and for centers for disease control and prevention staff.

Experts' consensus on immunization with meningococcal vaccines in China / 中华预防医学杂志

Meningococcal vaccines in the Chinese market include meningococcal polysaccharide vaccine, meningococcal polysaccharide conjugate vaccine, and a combined vaccine. Meningococcal conjugate vaccines immunization schedules vary by vaccine manufacturer, and often cause confusion in immunization practices. Based on the epidemiological characteristics of meningococcal disease, serogroup distribution of Neisseria meningitidis, and research progress on the immunogenicity and safety of meningococcal vaccines, we developed an experts' consensus on immunization with meningococcal vaccines to provide guidance for immunization providers and for centers for disease control and prevention staff.

Analysis of epidemic characteristics for meningococcal meningitis in China during 2015-2017 / 中华预防医学杂志

Objective@#To analyze the characteristics of epidemiology and neisseria meningitidis (Nm) serogroups distribution for meningococcal meningitis (MM) cases in China from 2015 to 2017.@*Methods@#The data of MM cases were collected from National Notifiable Diseases Registry System (NNDRS) and case-based MM surveillance system (MMSS) from 2015 to 2017; Demographic data are from the National Bureau of statistics. Inclusion criteria: the date of onset was January 1, 2015 to December 31, 2017, the status of infectious disease report card was "final examination card", the cases are classified as "laboratory confirmed cases" and "clinical diagnostic cases", and the card data information of disease name was "Meningococcal meningitis". According to the Diagnostic Criteria for Meningococcal meningitis (WS295-2008), laboratory confirm was made for reported cases or clinically diagnosed cases of meningococcal meningitis.@*Results@#From 2015 to 2017, a total of 325 MM cases were reported in China, with an average annual incidence of 0.007 9 per 100 000 population. And 148 cases were laboratory confirmed. There were 3, 15, 12, 5, 2 and 18 provinces which were reported serogroup A, B, C, W, Y, Others and NG MM Cases, respectively. Except for Tibet and Hainan, other provinces have reported group A cases; The provinces reporting group B, C, W and Y cases increased by 9, 11, 13 and 2 provinces in 2007, respectively compared with 2005. Serogroup B was the primary reason causing the cases of <1 year old and 1-6 years old children; and in this age group, 51.43% (18 cases) and 68.18% (15 cases) of group B were accounted for in laboratory confirmed, respectively; Serogroup C, others and NG was the major reason in the cases of 7-12 and >12 years old students and adults: 33.33% (5 cases) and 26.32% (20 cases) of group C were accounted for in laboratory confirmed respectively, then 26.67% (4 cases) and 34.21% (26 cases) of group others and NG were accounted for respectively; 2 cases of serogroup Y were all >12 years old.@*Conclusion@#The epidemic serogroup of Nm caused MM cases showed a diversifying trend. To develop and provide new vaccines for serogroup B and other bacteria groups should be one of the important tasks for MM control and prevention in the future.

Experts′ consensus on immunization with meningococcal vaccines in China / 中华预防医学杂志

Meningococcal vaccines in the Chinese market include meningococcal polysaccharide vaccine, meningococcal polysaccharide conjugate vaccine, and a combined vaccine. Meningococcal conjugate vaccines immunization schedules vary by vaccine manufacturer, and often cause confusion in immunization practices. Based on the epidemiological characteristics of meningococcal disease, serogroup distribution of Neisseria meningitidis, and research progress on the immunogenicity and safety of meningococcal vaccines, we developed an experts′ consensus on immunization with meningococcal vaccines to provide guidance for immunization providers and for centers for disease control and prevention staff.

Epidemiología de la enfermedad por meningococo en Colombia / Epidemiology of meningococcal disease in Colombia

Objetivo: Describir la situación epidemiológica de la enfermedad meningocócica en Colombia. Material y métodos: Estudio descriptivo que recopiló información de diferentes fuentes pertenecientes al Sistema Nacional de Vigilancia en Salud Pública. Las variables fueron analizadas de forma descriptiva y se calcularon las tasas de incidencia cuando los datos requeridos estuvieron disponibles. Resultados: Durante el periodo 2005-2011 se notificaron 1.065 casos, lo que representó un promedio anual de incidencia de 0,36/100.000 habitantes. De estos, se confirmaron tan solo el 46%, lo que apunta a la existencia de una importante brecha de notificación y confirmación. La mayor incidencia se encontró en menores de un año (5,4-6,9/100.000 habitantes) y el 50% de los casos se presentaron en menores de 10 años. Discusión: La Neisseria meningitidis serogrupo B representó la mayor proporción de los aislamientos; sin embargo, en los últimos años los serogrupos Y y C han tenido un repunte importante. Los síntomas fueron en general inespecíficos, el curso de la enfermedad fue rápido y la letalidad fue alta (13,3%). Conclusiones: Existe la necesidad de mejorar las herramientas disponibles para la vigilancia. Las acciones preventivas deben estar dirigidas a lactantes y niños, con protección contra los serogrupos Y y C. Es necesaria la investigación de estrategias contra el serogrupo B.

Objectives: The purpose of this paper was to describe the epidemiology of meningococcal disease in Colombia. Materials and methods: This was a descriptive study based on data from various sources in the National Surveillance System. The variables were analysed descriptively and the incidence rates were estimated when the required data were available. Results: During the 2005-2011 period, 1,065 cases were reported, which represented an annual mean incidence of 0.36/100.000 inhabitants. Of these, only 46% were confirmed, which reveals a gap between reporting and confirmation. The greatest incidence was observed in infants younger than one year (5.4-6.9/100,000) and 50% of the cases occurred in children under 10 years of age. Discussion: Neisseria meningitidis serogroup B represented the greatest proportion of isolates; however, serogroups Y and C have been increasing recently. The symptoms were non-specific, the course of the disease was rapid and the lethality high (13.3%). Conclusions: There is a need to improve the available tools for diagnosis and surveillance. Prevention must be oriented toward infants, toddlers and children including protection against serogroups C and Y. Research into strategies for prevention against serogroup B is also necessary.

Neisseria meningitidis presenting as acute abdomen and recurrent reactive pericarditis

ABSTRACT Meningococcal meningitis is a well established potential fatal infection characterized by fever, headache, petechial rash, and vomiting in the majority of cases. However, protean manifestations including abdominal pain, sore throat, diarrhea and cough, even though rare, should not be overlooked. Similarly, although disseminated infection could potentially involve various organ-targets, secondary immune related complications including joints or pericardium should be dealt with caution, since they remain unresponsive to appropriate antibiotic regimens. We hereby report the rare case of an otherwise healthy adult female, presenting with acute abdominal pain masking Neisseria meningitidis serotype B meningitis, later complicated with recurrent reactive pericarditis despite appropriate antibiotic treatment. There follows a review of current literature.

Meningitis neonatal por Neisseria meningitidis serogrupo B / Neonatal meningitis caused by serogroup B Neisseria meningitides

La meningitis meningocóccica es una infección poco frecuente en el período neonatal internacionalmente, y solo hay una publicación previa en la literatura médica cubana hace 25 años atrás, de recién nacidos con meningitis bacteriana causada por Neisseria meningitidis. Se presenta el caso de un recién nacido febril, con manifestaciones de toxicidad, fontanela abombada, y cuando se realizó punción lumbar, se encontró pleocitosis del líquido cefalorraquídeo y se aisló N. meningitidis serogrupo B, por lo que se diagnostica meningitis meningocóccica neonatal. Tuvo evolución favorable. Se describen algunas características de la infección meningocócica, y se destaca el diagnóstico y tratamiento recomendado para este tipo de infección, así como se hace referencia a reportes de casos publicados en la literatura internacional.

Meningoccocal meningitis is a rare infection in the neonatal period worldwide and there is just one publication in the Cuban medical literature dated 25 years ago, which presented some neonates with bacterial meningitis caused by Neisseria meningitides. This is a febrile neonate with toxicity manifestations and bulging fontanelle; he was performed a lumbar puncture to find spinal fluid pleocytosis and the serogroup B N. meningitides was then isolated, so he was diagnosed with neonatal meningococcal meningitis with favorable progression. Some characteristics of the meningococcal infection, the diagnosis and recommended treatment were described in addition to making reference to case reports published in the international literature.

Trends of meningococcal meningitis with Neisseria meningitidis in Shijiazhuang, 1949-2014 / 中华传染病杂志

Objective To study the trends over time in meningococcal meningitis with Neisseria meningitidis .Methods Routine reported data on Meningococcal meningitis with Neisseria meningitidis in Shijiazhuang from 1949 to 2014 were used to study the trends of disease severity,disease distribution and serogroup switching of Neisseria meningitidis strains over time.The qualitative description and the quantitative evaluation was performed by the annual percent change (APC)in incidence to demonstrate the secular trends.The t test and χ2 test were performed when appropriate.Results From 1949 to 2014, 53 779 meningococcal meningitis cases were reported in Shijiazhuang.Of the 53 779 cases,36 170 were male and 17 609 were female,which was significantly different (χ2 =581 .04,P =0.000).It occurred all the year round,with an increased incidence between February and April,accounting for 81 .44%.The epidemic peak occurred about every 10 years.The range of annual incidence rate was from 0.01/lakh to 387.21/lakh.APC was -4.65 (t=-11 .72,P =0.000).The significant decline of APC were found in the age group of 0—1 year (t=-10.56,P =0.000),1 —5 year (t =-14.32,P =0.000),5 —10 year (t=-11 .01 ,P =0.003 ),10—15 year (t = -8.34,P =0.033 )and 40—50 year (t = -7.42,P =0.045).The risk population was those under 5 years old during 1949 to 2002 period and the serogroup was dominated by A strains.Whereas during 2003 to 2014,that was those of 5 —15 years old,and the dominant serogroup was C strains. Conclusions There is a remarkable decline in incidence of meningococcal meningitis in Shijiazhuang.The serogroup changes from A strains to C strains and the risk population of cases shifts to older children.

Antigen sequence typing of outer membrane protein (fetA) gene of Neisseria meningitidis serogroup A from Delhi & adjoining areas.

Background & objectives: Meningitis caused by Neisseria meningitidis is a fatal disease. Meningococcal meningitis is an endemic disease in Delhi and irregular pattern of outbreaks has been reported in India. All these outbreaks were associated with serogroup A. Detailed molecular characterization of N. meningitidis is required for the management of this fatal disease. In this study, we characterized antigenic diversity of surface exposed outer membrane protein (OMP) FetA antigen of N. meningitidis serogroup A isolates obtained from cases of invasive meningococcal meningitis in Delhi, India. Methods: Eight isolates of N. meningitidis were collected from cerebrospinal fluid during October 2008 to May 2011 from occasional cases of meningococcal meningitis. Seven isolates were from outbreaks of meningococcal meningitis in 2005-2006 in Delhi and its adjoining areas. These were subjected to molecular typing of fetA gene, an outer membrane protein gene. Results: All 15 N. meningitides isolates studied were serogroup A. This surface exposed porin is putatively under immune pressure. Hence as a part of molecular characterization, genotyping was carried out to find out the diversity in outer membrane protein (FetA) gene among the circulating isolates of N. meningitidis. All 15 isolates proved to be of the same existing allele type of FetA variable region (VR) when matched with global database. The allele found was F3-1 for all the isolates. Interpretation & conclusions: There was no diversity reported in the outer membrane protein FetA in the present study and hence this protein appeared to be a stable molecule. More studies on molecular characterization of FetA antigen are required from different serogroups circulating in different parts of the world.

Invasive meningococcal disease / Doenca meningococica invasiva

Invasive meningococcal disease (IMD) is a major public health and continues to cause substantial mortality and morbidity. Serotype C is the most frequent in Brazil. The clinical spectrum of IMD is broad (meningitis, meningococcemia or both) and the clinical evolution may be unpredictable. Main features associated with mortality are: age higher than 50 years old, seizures, shock, and meningococcemia without meningitis. Blood cultures should be obtained immediately. Lumbar puncture can be performed without previous computed tomography scan (CT) in most cases. Clinical features can be useful to predic patients where an abnormal CT scan is likely. Cerebrospinal fluid (CSF) culture and Gram stain should always be required. Latex agglutination sensitivity is highly variable. Polymerase chain reaction is specially useful when other methods are negative or delayed. Usually ceftriaxone should not be delayed while awaiting CSF study or CT. Dexamethasone can be used in meningococcal meningitis. Early suspicion of IMD and antibiotic in primary care before hospitalization, rapid transportation to a hospital, and stabilization in an intensive-care unit has substantially reduced the case-fatality rate. Vaccines against serotypes A, C, W-135, and Y are available while vaccines against serotype B are expected.

A doença meningocócica invasiva (DMI) é um problema de saúde pública e continua causando importante mortalidade e morbidade. O sorotipo C é o mais frequente no Brazil. O espectro clínico da DMI é amplo (meningite, meningococcemia ou ambos) e a evolução clínica pode ser imprevisível. As principais características associadas a mortalidade são: idade acima de 50 anos, convulsões, choque, e meningococcemia sem meningite. Culturas de sangue devem ser obtidas imediatamente. Punção lombar pode ser realizada sem tomografia computadorizada (TC) prévia na maioria dos casos. Características clínicas podem ajudar a predizer pacientes com elevada probabilidade de apresentar TC alterada. Cultura e Gram no líquido cefalorraquiano devem ser sempre solicitadas. Aglutinação do látex apresenta sensibilidade muito variável. Reação em cadeia da polimerase é especialmente útil quando os outros métodos são negativos ou demorados. O uso de ceftriaxona não deve ser retardado enquanto se esperam os resultados do líquor ou TC. Dexametasona pode ser utilizada na meningite meningococóca. Suspeita precoce de DMI, antibiótico no primeira atendimento, antes da admissão hospitalar, transporte rápido para hospital, e estabilização em unidade de terapia intensiva reduz substancialmente a taxa de letalidade. Vacinas contra os sorotipos A, C, W-135, e Y estão disponíveis, entretanto, vacinas contra o sorotipo B são esperadas.

Caracterización clínica de los casos de enfermedad meningocóccica por serogrupo W135 confirmados durante el año 2012 en Chile / Clinical characterization of cases with meningococcal disease by W135 group in Chile, 2012

Background: During 2012 in Chile, there were 60 cases of serogroup W135 meningococcal disease, which accounts for 57.7% of identified serogroup cases. Aim: To describe main clinical features of patients with serogroup W135 meningococcal disease confirmed in 2012. Material and Methods: Descriptive study of case series based on retrospective review of medical records. Results: Male patients represented 61.7% and 46.7% were children under 5 years. At first clinical attention, 3.4% of patients were suspected of meningococcal disease, while 83.3% had meningococcemia as final diagnosis. Also at first attention, the most common symptoms or clinical signs were fever ≥ 38.0° C (60.3%), cold symptoms (52.5%), and nausea or vomiting (46.7%). Meningeal signs had a low frequency (8.7%). Diarrhea was the second most common symptom found among deceased patients (55.6%) and statistically higher than survivors (26.8%; p = 0.034). Six cases reported with sequelae: limb amputation, hearing loss or neurological damage, and mortality was 31.7%. Discussion: In 2012, serogroup W135 meningococcal disease reported high mortality, atypical clinical presentation, low initial meningococcal disease diagnosis, and a high number of cases with poor clinical course.

Introducción: En el año 2012 en Chile, se presentaron 60 casos de enfermedad meningocóccica (EM) causadas por serogrupo W135, que representa 57,7% de los casos seroagrupables. Objetivo: Describir las características clínicas de los casos de EM por serogrupo W135 confirmados durante el año 2012. Material y Métodos: Estudio descriptivo, de series de casos basada en la revisión de las fichas clínicas. Resultados: El 61,7% de los casos fueron varones y 46,7% tenía menos de 5 años. En la primera consulta, 3,4% tuvo sospecha de EM, en tanto 83,3% tuvo diagnóstico final de meningococcemia. En la primera consulta, los síntomas y/o signos más frecuentes fueron fiebre ≥ 38,0°C (60,3%), cuadro catarral respiratorio (52,5%) y náuseas y/o vómitos (46,7%). Mientras que los signos de irritación meníngea se presentaron en 8,7%. En los fallecidos la diarrea fue el segundo síntoma más frecuente (55,6%), y estadísticamente superior respecto de los sobrevivientes (26,8%; p = 0,034). Seis casos presentaron secuelas: amputaciones de extremidades, hipoacusia o daño neurológico y la letalidad fue de 31,7%. Discusión: la EM por el serogrupo W135 en el año 2012, tuvo una elevada letalidad, presentación clínica inespecífica, sospecha diagnóstica inicial baja y un alto número de casos cursaron con una mala evolución.

A doença meningocócica na região de Sorocaba, São Paulo, Brasil, no período de 1999 a 2008 / Meningococcal disease in the Sorocaba region, São Paulo State, Brazil, 1999-2008

O objetivo do estudo foi descrever a ocorrência da doença meningocócica notificada no Departamento Regional de Saúde XVI, Sorocaba, São Paulo, Brasil, no período de 1999 a 2008. Em Sorocaba, a incidência anual da doença foi de cerca de dois casos por 100 mil habitantes, com aumento entre 2006 e 2008. As incidências anuais foram maiores entre 0 a 4 anos de idade. A letalidade no período foi de 21,8%, maior nas faixas etárias de 0 a 4 anos (26,4%), na qual se deu a maior incidência da doença, e com idade superior a 30 anos (28%). A confirmação diagnóstica foi laboratorial em 71% dos casos (cultura em 45,3%) e por critérios clínico-epidemiológicos em 22%. O sorogrupo B ocorreu em 45,7%; o C, em 47,3%; o W135, em 3,7%; e o Y, em 1,5% dos casos identificados, com predomínio do sorogrupo B, entre 1999 e 2003, e do C, entre 2004 e 2008. Os fenótipos B:4,7:P1.19,15 e C:23:P1.14-6 predominaram. Os resultados reforçam a necessidade de acompanhamento, de forma regional, da tendência da doença para a detecção de surtos precocemente e monitoramento de cepas circulantes.

The objective of this study was to describe the occurrence of meningococcal disease reported to the Regional Health Department in Sorocaba, São Paulo State, Brazil, from 1999 to 2008. Annual incidence of the disease was two cases per 100,000 inhabitants, with an increase from 2006 to 2008. Annual incidence rates were highest in the 0 to 4 year age bracket. Case-fatality was 21.8%, higher in the 0 to 4 year age bracket (26.4%), which also showed the highest incidence of the disease, and in the over 30-year age bracket (28%). Diagnosis was confirmed by laboratory test in 71% of cases (culture in 45.3%) and by clinical and epidemiological criteria in 22%. Serological groups were B in 45.7%, C in 47.3%, W135 in 3.7%, and Y in 1.5% of the identified cases, with a predominance of B from 1999 to 2003 and C from 2004 to 2008. The most frequent phenotypes were B:4,7:P1.19,15 and C:23:P1.14-6. The results emphasize the need for regional surveillance of trends in the disease for early detection of outbreaks and monitoring circulating strains.

Epidemiological profile of meningococcal disease in the State of Minas Gerais and in the Central, North, and Triângulo Mineiro regions, Brazil, during 2000-2009 / Perfil epidemiológico da doença meningocócica, no Estado de Minas Gerais e nas regiões Centro, Norte e Triângulo Mineiro, Brasil, de 2000 a 2009

INTRODUCTION: Infection by Neisseria meningitidis, termed as meningococcal disease, can cause meningococcal meningitis and septicemia with or without meningitis. Meningococcal disease is endemic in Brazil and has a high potential to cause large-scale epidemics; therefore, it requires the immediate notification of cases to the Information System for Notifiable Diseases (SINAN) in Brazil. The aim of this study was to describe an epidemiological profile using data from notified and confirmed cases in the State of Minas Gerais, Brazil, from January 2000 to December 2009, obtained from the investigation records of individuals with meningitis registered with SINAN. METHODS: This was a retrospective, population-based study. Descriptive analysis of the data was made using the simple and relative frequencies of the categorical variables in the investigation records. RESULTS: There were 1,688 confirmed patients in Minas Gerais of which 45.5% lived in the Central, North, and Triângulo Mineiro regions. The highest frequencies of cases were in the 1-4-years age group (26.3%), males (54.7%), caucasian (36.4%), and lived in an urban area (80%). In the patients with specified education, 650 (60.9%) patients had secondary education. Serogrouping of meningococci had been performed in 500 (29.6%) patients by age and gender; 285 (57%) belonged to serogroup C, 67 (13.4%) were in the 1-to 4-years age group, and 168 (33.6%) were male. CONCLUSIONS: The epidemiological profiles of patients in the Central, North, and Triângulo Mineiro regions were not significantly different from the profile of patients in Minas Gerais.

INTRODUÇÃO: A infecção por Neisseria meningitidis, denominada doença meningocócica, pode causar meningite meningocócica e meningococcemia com ou sem meningite. A doença meningocócica é endêmica no Brasil; no entanto, o alto potencial de causar epidemias e letalidade elevada impõe a notificação imediata dos casos ao Sistema de Informação de Agravos de Notificação (SINAN) do Brasil. O objetivo deste estudo foi descrever o perfil epidemiológico, utilizando registros de casos notificados e confirmados no Estado de Minas Gerais, Brasil, de janeiro de 2000 a dezembro de 2009, obtidos a partir da ficha individual de investigação de meningites registrada no SINAN. M ÉTODOS: Trata-se de um estudo retrospectivo, de base populacional. Foram realizadas análises descritivas dos dados, a partir das frequências simples absolutas e relativas para as variáveis categóricas da ficha de investigação e teste qui-quadrado. RESULTADOS: Houve 1.688 casos confirmados em Minas Gerais, dos quais 45,5% residiam no centro, norte e Triângulo Mineiro. As maiores frequências foram nos pacientes do grupo etário de 1 a 4 anos (26,3%), sexo masculino (54,7%), brancos (36,4%) e residiam em zona urbana (80%). Dos casos com escolaridade especificada, 650 (60,9%) casos cursaram ensino médio completo. Foram sorogrupados e classificados segundo idade e sexo 500 (29,6%) casos, e desses 285 (57%) foram sorogrupo C, 67 (13,4%) da faixa etária de 1 a 4 anos e 168 (33,6%) do sexo masculino. CONCLUSÕES: O perfil epidemiológico dos casos nas regiões centro e norte e Triângulo Mineiro não apresentaram diferenças importantes comparado ao perfil dos casos de Minas Gerais.

Avaliação do complemento na doença meningocócica / Assessment of complement in meningococcical disease

Avaliar aspectos do sistema imunológico inato na doençameningocócica, com enfase nas frações C3, C4 e o CH50 do sistema imunológico e lectina ligadora de manose (MBL) com ênfase na pediatria. Fonte de dados: Revisão narrativa de periódicos na área de infectologia e imunologia sobre o assunto nos últimos 10 anos e pesquisas anteriores a esta data com relevância segundo a avaliação dos autores. Síntese dos dados: O acometimento da imunidade humoral é predominante nas Imunodeficiências Primárias, mas quando se considera apenas os casos de doença meningocócica as deficiências de complementosão presumivelmente as mais frequentes. Conclusões: A deficiência de componentes do sistema complementoe alterações decorrentes do polimorfismo gênico da MBL 2 são possíveis explicações para o desenvolvimento de doença meningocócica em algunspacientes. Assim a avaliação do complemento pode ser necessária para indivíduos que foram acometidos por esta grave doença.

Evaluate some aspects of the innate immune system of patients with a history of meningococcal disease, being chosen from among them the complement fractions C3, C4 and CH50 than the evaluation of the mannose-binding lectin (MBL) gene with emphasis on pediatrics. Data source: Review of journals in the field of infectious diseases and immunology on the subject in the last 10 years or before that dateby relevance. Data synthesis: Involvement of humoral immunity is predominant in primary immunodeficiencies, but complement deficiencies are presumably the most frequent when considering only cases of meningococcal disease.Epidemiological aspects, clinical and immunological designed to discuss the subject. Conclusions: Complement deficiency and polymorphism in the MBL2 gene are possible explanations for the development of meningococcaldisease in some patients. So the evaluation of the supplement maybe suggestible with exceptions for individuals affected by this seriousdisease.

Desenvolvimento e avaliação de modelo computacional para geração de alertas a partir de notificações de casos de meningite meningocócica / Development and evaluation of a computing model of alerts from meningococcal meningitis notification cases

INTRODUÇÃO: este trabalho apresenta a arquitetura de um sistema de emissão de alertas para surtos e epidemias em tempo real, baseado em notificações eletrônicas da meningite, e discute os resultados dos testes e simulações realizados. MÉTODOS: esse sistema foi desenvolvido em quatro etapas: Concepção, Análise, Construção e Teste/Simulações. A Concepção contemplou a elicitação de requisitos, a qual definiu o que o sistema deve fazer. A Análise se preocupou com a modelagem e especificação das regras que definem como o sistema deve trabalhar. A Construção abrangeu a transformação das regras definidas e modeladas em linguagem de programação. A última etapa, Teste/Simulação, foi responsável por garantir que o sistema construído estava em conformidade com os requisitos elicitados na etapa de Concepção. RESULTADOS: vários artefatos foram criados e algumas constatações foram verificadas nesta etapa. Sobre os artefatos podemos citar os requisitos, casos de uso, diagrama de classes, modelo físico de dados, casos de teste e programas. Sobre as constatações podemos citar o disparo de alertas nas simulações realizadas pelo sistema dois dias antes que o alerta feito pelas autoridades de saúde do Estado de São Paulo usando os procedimentos habituais. DISCUSSÃO e CONCLUSÃO: O sistema desenvolvido pode ser classificado como um Early Warning System. Nas simulações, observamos que em duas oportunidades ele conseguiu evidenciar ocorrência de surto antecipadamente ao método tradicional utilizado pelo Centro de Vigilância Epidemiológico de São Paulo. Comparando-o com sistemas semelhantes em produção, verificamos que esse sistema se diferencia ao emitir ativamente alertas de surtos em tempo real.

INTRODUCTION: this essay presents the architecture of an alert system for epidemics based on real-time electronic notification of meningococcal meningitis, and discusses the results of tests and simulations made. METHODS: this system was developed in four stages: Conception, Analysis, Construction and Test/Simulation. The Conception covered the requirements elicitation, which defined what the system should do. The Analysis involved the modeling and specification rules that defined how the system should work. The Construction covered the transformation of defined and modeled rules in programming language. The last stage, Test/Simulation, checked the system under known scenarios, comparing the timing of outputs with the Brazilian notification surveillance framework. RESULTS: many artifacts were made and some evidences were verified. About the artifacts we can mention the requirements, use cases, class diagram, physical data model, test cases, and algorithms. About the evidences we can mention the fast alert production in simulations of this system as compared with the current procedure in use by health authorities. DISCUSSION AND CONCLUSION: this system can be classified as an Early Warning System. In simulations we observed that in two opportunities, it managed to put in evidence outbreak occurrence in advance to the traditional used method by Epidemiological Surveillance Center of São Paulo. In comparison with the similar systems under operation, we note this system is distinguished from them in issuing real-time outbreak alerts.

Effectiveness of an immunization campaign with group A and C meningococcal polysaccharide vaccine in controlling an outbreak of group C meningococcal disease / 中华流行病学杂志

Objective To assess the safety, immunogenicity and efficacy of group A and C meningococcal polysaccharide vaccine (A/C MPV) in response to an outbreak of group C meningococcal disease. Methods A vaccination campaign with A/C MPV was prompted 6 weeks after the use of group A MPV in Laibin city, Guangxi, where an outbreak of group C meningococcal meningitis occurred in 2002.Vaccinees were observed for local and systemic reactions after the vaccination and followed up for the meningococcal disease for 5 years. Blood samples were collected from 71 people in the epidemic and 43 in the non-epidemic areas before and 1 month after the vaccination and examined by ELISA to detect IgG antibodies to group A and C polysaccharides. Results The vaccination coverage was 97%. No significant adverse reactions were observed. The positive rates of group C antibodies after vaccination was between 97.67% and 100% among the populations in the epidemic and non-epidemic areas, as well as among those negative and positive for group C antibodies prior to the vaccination.The geometric mean anti-C concentrations ranged 30.81 μg/ml to 37.44 μg/ml, showing no significant difference between groups. The incidence rate of meningococcal disease in students with timely immunization (218.58/100 000) dropped by 69.02% , when compared to that in those with delayed immunization (705.72/100 000). No clinical cases were identified during the follow-up period of 15 760 person-years. Conclusion The vaccination campaign with the Chinese group A/C MPV seemed successful in controlling the group C meningococcal outbreak.The vaccine was shown to be safe even administered after the group A vaccine only 6 weeks apart. It could induce high levels of antibodies in vulnerable population and significantly increase antibody levels in seropositive individuals, thus providing a protection of at least 5 years.